Cutaneous neoplasia in organ transplant recipients

Current Problems in Dermatology

Volumn 11, Issue 4, 1999, Pages 152-158

  Ida, Orengo ^a   Brown, Tricia ^a   Rosen, Theodore ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746577380     PISSN: 10400486     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (191)

1. Crumbley AJ III, Bromberg JS, Cofer JB, et al. Medical aspects of transplantation. J S C Med Assoc 1991;87:313-28.
2. Hayes JM. The immunobiology and clinical use of current immunosuppressive therapy for renal transplantation. J Urol 1993:149:437-48.
3. Shiel AGR, Disney APS, Mathew TH, et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993;25:1383-4.
4. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1994;7:99-109.
5. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991;23:1101-3.
6. Shell AGR, Disney APS, Mathew TH, et al. Cancer development in cadaveric donor renal allograft recipients treated with azathioprine or cyclosporine or azathioprine/cyclosporine. Transplant Proc 1991;23:llll-2.
7. US Bureau of the Census. Statistical abstract of the United States: 1996. 16th ed. Washington: The Bureau; 1996.
8. United Network for Organ Sharing. Numbers of US transplants: 1988-May, 1997. Available at: http://www.unos.org/sta_tran.htm. Accessed Nov 6, 1997.
9. Lu L. Commerce in organ transplantation. Pharos 1998 Spring; 61(2):2-5.
10. European Transplant Coordinators Organization. Solid organ transplants in Europe-1996. Available at: http://www.kuleuven.ac.be/facdep/medicine/etco/STATISTICS/Compar isonEurUSA.html. Accessed Nov 6, 1997.
11. Daar AS. Developments in immunosuppressive therapy. Transplant Proc 1995;27:2671-5.
12. Oka T, Yoshimura N. Immunosuppression in organ transplantation. Jpn J Pharmacol 1996;71:89-100.
13. Mycophenolate mofetil for the transplanted kidney? Drug Ther Bull 1997;35:38-40.
14. Briggs JD. A critical review of immunosuppressive therapy. Immunol Lett 1991;29:89-94.
15. Mérot Y, Miescher PA, Balsiger F, et al. Cutaneous malignant melanomas occurring under cyclosporin A therapy: a report of two cases. Br J Dermatol 1990;123:237-9.
16. Graham RM. Cyclosporine: mechanisms of action and toxicity. Cleve Clin J Med 1994;61:308-13.
17. Thompson AW. The immunosuppressive macrolides FK-506 and rapamycin. Immunol Lett 1991;29:105-12.
18. Blazer BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 1997;157:79-109.
19. Goral S, Helderman JH. The evolution and future of immunosuppression in renal transplantation. Semin Nephrol 1997;17:364-72.
20. Vanrenterghem Y. The use of mycophenolate mofetil (Cellcept®) in renal transplantation. Nephron 1997;76:392-9.
21. Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy 1997;17:1178-97.
22. Perico N, Remuzzi G. Prevention of transplant rejection: current treatment guidelines and future developments. Drugs 1997:54:533-70.
23. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolate acid and predicted longterm effects of mycophenolate mofetil in transplantation. Transplant Proc 1994;3205-10.
24. Taylor DO, Ensley RD, Olsen SL, et al. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three year experience in heart transplantation. J Heart Lung Transplant 1994;13:571-83.
25. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981:41:4253-61.
26. Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection. Transplantation 1998;65:235-41.
27. Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986:122:1288-93.
28. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow up study. Transplantation 1996:61:715-21.
29. Bouwes Bavinck JN, De Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993;129:242-9.
30. Penn I. Skin disorders in organ transplant recipients. Arch Dermatol 1997;133:221-3.
31. Bourke JF, Mellott GJ, Young G, et al. Skin cancer in an Irish renal transplant population. Ir J Med Sci 1992;161:116-7.
32. Salasche SJ, Cheney ML, Varvares MA. Recognition and management of the high-risk cutaneous squamous cell carcinoma. Curr Probl Dermatol 1993:5:147-89.
33. McGregor JM, Proby CM. Skin cancer in transplant recipients. Lancet 1995;346:964-5.
34. Barrett WL, First MR, Aron BS, et al. Clinical course of malignancies in renal transplant recipients. Cancer 1993;72:2186-9.
35. Shell AGR, May J, Mahoney JF, et al. Incidence of cancer in renal transplant recipients. Proc Eur Dial Transplant Assoc 1980:17:502-6.
36. Euvrard S, Chardonnet Y, Pouteil-Noble C. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients. Cancer 1993:72:2198-206.
37. Kinlen LJ, Sheil AGR, Peto J, et al. Collaborative United Kingdom-Australian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979;2:1461-6.
38. Glover MT, Niranjan N, Kwan JTC, et al. Nonmelanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 1994;47:86-9.
39. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995:27:1767-8.
40. Dyall-Smith D, Ross JB. Cutaneous malignancies in renal transplant recipients from Nova Scotia, Canada. Australas J Dermatol 1995;36:79-82.
41. Roeger LS, Shell AGR, Disney APS, et al. Risk factors associated with the development of squamous cell carcinomas in immunosuppressed renal transplant recipients. Clin Transpl 1992;6:202-11.
42. Kricker A, Armstrong B, English D, et al. Pigmentary and cutaneous factors for non-melanotic skin cancer - a case-control study. Int J Cancer 1991;48:650-2.
43. Marks R, Kolley D, Lectas S, et al. The risk of childhood exposure to sunlight in the development of solar kératoses and non-melanotic skin cancer. Med J Aust 1990;152:62-6.
44. Gruber SA, Gillingham K, Sothern RB, et al. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transpl 1994;8:388-95.
45. Kessler II. Cancer and diabetes mellitus: a review of the literature. J Chron Dis 1971;23:579-600.
46. Ragozzino M, Melton LJ, Chu CP, et al. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chron Dis 1982:35:13-9.
47. Penn I. De novo malignancy in pédiatrie organ transplant recipients. J Pediatr Surg 1994;29:221-8.
48. McGregor JM, Barker JN, MacDonald DM. The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. Clin Exp Dermatol 1991;16:131-2.
49. Szepietowski J, Wasik F, Szepietowski T, et al. Excess benign melanocytic naevi in renal transplant recipients. Dermatology 1997;194:17-9.
50. Greene MH, Young TI, Clark WH Jr. Malignant melanoma in renal-transplant recipients. Lancet 1980;1: 1196-9.
51. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996;61:274-8.
52. Penn I. Effect of immunosuppression on preexisting cancers. Transpl Proc 1993;25:1380-2.
53. Formica M, Basolo B, Funaro L, et al. Merkel cell carcinoma in renal transplant recipient. Nephron 1994;63:399.
54. Strumia R, Perini L, Tarroni G, et al. Skin lesions in kidney transplant recipients. Nephron 1992:62:137-41.
55. Jensen P, Clausen OFF, Geiran O, et al. Cutaneous complications in heart transplant recipients in Norway 1983-1993. Acta Derm Venereol Suppl (Stockh) 1995:75:400-3.
56. Chugh KS, Sharma SC, Singh V, et al. Spectrum of dermatological lesions in renal allograft recipients in a tropical environment. Dermatology 1994;188:108-12.
57. Glover M, Cerio R, Corbett M, et al. Cutaneous squamoproliferative lesions in renal transplant recipients. Am J Dermatopathol 1995:17:551-4.
58. Blohrne I, Larkö O. Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. Acta Derm Venereol Suppl (Stockh) 1990:70:491-4.
59. Ferrändiz C, Fuente MJ, Ribera M, et al. Epidermal dysplasia and neoplasia in kidney transplant recipients. J Am Acad Dermatol 1995;33:590-6.
60. Paquet P, Piérard GE. Invasive atypical fibroxanthoma and eruptive actinie kératoses in a heart transplant patient. Dermatology 1996;192:411-3.
61. Besnard V, Euvrard S, Kanitakis J, et al. Kaposi's sarcoma after liver transplantation. Dermatology 1996:193:100-4.
62. Pedagogos E, Nicholls K, Dowling J, et al. Kaposi's sarcoma post renal transplantation. Aust N Z J Med 1994;24:722-3.
63. Orozco-Topete R, Archer-Dubon C, Valadez Huerta N, et al. Cutaneous neoplasms and human papillomavirus in renal transplant patients: experience of one center in Mexico. Transplant Proc 1996;28:3314-6.
64. Montagnino G, Bencini PL, Tarantino A, et al. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report of 13 cases. Am J Nephrol 1994;14:121-6.
65. Friedman-Kien A, Satzman BR. Clinical manifestations of classical, endemic, African, and epidemic AIDS-associated Kaposi's sarcom. J Am Acad Dermatol 1990;22:1237-50.
66. Touraine JL, Gamier JL, Lefrancois L, et al. Severe lymphoproliferative disease and Kaposi's sarcoma in transplant patients. Transplant Proc 1989;21:3197-8.
67. Euvrard S, Chardonnet Y, Dureau G, et al. Human papillomavirus type 1-associated squamous cell carcinoma in a heart transplant recipient. Arch Dermatol 1991;127:559-64.
68. Ozen S, Saatci U, Karaduman A, et al. Kaposi sarcoma in a paediatric renal transplant recipient. Nephrol Dial Transplant 1996 :11:1162-3.
69. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997;64:669-73.
70. Aebischer MC, Zala LB, Braathen LR. Kaposi's sarcoma as manifestation of immunosuppression in organ transplant recipients. Dermatology 1997;195:91-2.
71. Halmos O, Inturri P, Galligioni A, et al. Two cases of Kaposi's sarcoma in renal and liver transplant recipients treated with interferon. Clin Transpl 1996;10:374-8.
72. Zahger D, Lotan C, Admon D, et al. Very early appearance of Kaposi's sarcoma after cardiac transplantation in Sephardic Jews. Am Heart J 1993;126:999-1000.
73. Shepherd FA, Mäher E, Cardella C, et al. Treatment of Kaposi's sarcoma after solid organ transplantation. J Clin Oncol 1997:15:2371-7.
74. Kibe Y, Kishimoto S, Katoh N, et al. Angiosarcoma of the scalp associated with renal transplantation. Br J Dermatol 1997:136:752-6.
75. Dargent JL, Vermylen P, Abramowicz D, et al. Disseminated angiosarcoma presenting as a hemophagocytic syndrome in a renal allograft recipient. Transpl Int 1997;10:61-4.
76. Bessis D, Sotto A, Roubert P, et al. Endothelin-secreting angiosarcoma occurring at the site of an arteriovenous fistula for haemodialysis in a renal transplant recipient [letter]. Br J Dermatol 1998;138:361-2.
77. Alpers CE, Biava CG, Salvatierra O. Angiosarcoma following renal transplantation. Transplant Proc 1982;14:448-51.
78. Askari A, Novick A, Braun W, et al. Late ureteral obstruction and hematuria from de novo angiosarcoma in a renal transplant patient. J Urol 1980;124:717-9.
79. Conlon PJ, Daly T, Doyle G, Carmody M. Angiosarcoma at the site of a ligated arteriovenous fistula in a renal transplant recipient. Nephrol Dial Transplant 1993;8:259-62.
80. Keane MM, Carney DN. Angiosarcoma arising from a defunctionalized arteriovenous fistula. J Urol 1993:149:364-5.
81. Medioni LD, Costes V, Leray H, et al. Angiosarcome sur fistule artério-veineuse chez un transplanté rénal: une complication inhabituelle. Ann Pathol 1996;16:200-2.
82. O'Connor JP, Quinn J, Wall D, et al. Cutaneous angiosarcoma following graft irradiation in a renal transplant patient [letter]. Clin Nephrol 1986;25:54-5.
83. Parrott NR, Scott PD, Freemont AJ, et al. Angiosarcoma in an arteriovenous fistula following successful renal transplantation: a case report. Transplantation 1993;55:676-7.
84. Couetil JP, McGoldrick JP, Wallwork J, et al. Malignant tumors after heart transplantation. J Heart Transplant 1990;9:622-6.
85. Barroso-Vicens E, Ramirez G, Rabb H. Multiple primary malignancies in a renal transplant patient. Transplantation 1996;61:1655-6.
86. Olivari MT, Diekmann RA, Kubo SH, et al. Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression. J Heart Transplant 1990;9:618-21.
87. Mozzanica N, Cattaneo A, Fracchiolla N, et al. Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction in immunosuppression. J Heart Lung Transplant 1997:16:964-8.
88. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995;33:222-9.
89. Mihalov ML, Gattuso P, Abraham K, et al. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996;10:248-55.
90. Lishner M, Patterson B, Kandel R, et al. Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer 1990;65:473-6.
91. Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, et al. Relation between skin cancer and HLA antigens in renaltransplant recipients. N Engl J Med 1991;325:843-8.
92. Penn I. Tumors after renal and cardiac transplantation. Hematol Oncol Clin North Am 1993;7:431-5.
93. Hiesse C, Larue JR, Kriaa P, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients. Transplant Proc 1995;27:2450-1.
94. Douds AC, Mellotte GJ, Morgan SH. Fatal Merkel-cell tumour (cutaneous neuroendocrine carcinoma) complicating renal transplantation. Nephrol Dial Transplant 1995;10;2346-8.
95. Glover MT, Deeks JJ, Raftery MJ, et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997:349:398.
96. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997;29;831-3.
97. Mouquet C, Benalia H, Ourahma S, et al. Incidence of non-cutaneous malignancies in kidney transplant recipients: a 20year follow-up. Transplant Proc 1995;27:1764.
98. Züniga-A V, Alvarez-A L, Diliz-P H. Neoplasia in renal transplantation. Transplant Proc 1996;28:3332.
99. Shuttleworth D, Marks R, Griffin PJA, et al. Epidermal dysplasia and cyclosporine therapy in renal transplant patients: a comparison with azathioprine. Br J Dermatol 1989;120:551-4.
100. Behrend M, Kolditz M, Kliem V, et al. Malignancies in patients under long-term immunosuppression after kidney transplantation. Transplant Proc 1997;29;834-5.
101. Barr BBB, McLaren K, Smith IW, et al. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989;l:124-9.
102. Espana A, Redondo P, Femândez AL, et al. Skin cancer in heart transplant recipients. J Am Acad Dermatol 1995;32: 458-65.
103. Penn I. Cancers following cyclosporine therapy. Transplantation 1987;43:32-5.
104. Sheil AGR, Hall BM, Tiller DJ, et al. Cyclosporine A versus standard therapy for cadaveric donor renal transplantation. Transplant Proc 1984;16:992-4.
105. Penn I, Brunson ME. Cancers after cyclosporine therapy. Transplant Proc 1988;20:885-92.
106. Blohmé I, Larkö O.' No difference in skin cancer incidence with or without cyclosporine-a five-year perspective. Transplant Proc 1992;24:313.
107. Bunney MH, Benton EC, Barr BB, et al. The prevalence of skin disorders in renal allograft recipients receiving cyclosporin A compared with those receiving azathioprine. Nephrol Dial Transplant 1990;5:379-82.
108. Gruber SA, Skjei KL, Sothern RB, et al. Cancer development in renal allograft recipients treated with conventional and cyclosporine immunosuppression. Transplant Proc 1991;23:1104-5.
109. Al-Sulaiman MH, Mousa DH, Dhar JM, et al. Does regressed post-transplantation Kaposi's sarcoma recur following reintroduction of immunosuppression? Am J Nephrol 1992;12:384-6.
110. Bouwes Bavinck JN, Claas FHJ. The role of HLA molecules in the development of skin cancer. Hum Immunol 1994;41:173-9.
111. Cancers in cyclosporine-treated vs azathioprine-treated patients. Transplant Proc 1996;28:876-8.
112. Taylor AEM, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol Suppl (Stockh) 1992;72:115-9.
113. Leigh IM, Glover MT. Skin cancer and warts in immunosuppressed renal transplant recipients. Recent Results Cancer Res 1995;139:69-86.
114. Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metabolites, I: 6-mercaptopurine. Photochem Photobiol 1986;43:247-55.
115. Hemmens VJ, Moore DE. Photochemical sensitization by azathioprine and its metablites, II: azathioprine and nitroimidazole metabolites. Photochem Photobiol 1986;43:257-62.
116. Streilein JW. Immunogenetic factors in skin cancer. N Engl J Med 1991:325:884-6.
117. Bergfeit L, Larkö O, Blohmé I. Skin disease in immunosuppressed patients in relation to epidermal Langerhans' cells. Acta Derm Venereol Suppl (Stockh) 1993;73:330-4.
118. Bouwes Bavinck JN, Kootte AMM, van der Woude FJ, et al. Skin cancer and keratotic skin lesions in renal transplant recipients. J Invest Dermatol 1991;97:269-72.
119. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78(1A Suppl):44-9.
120. Arellano F. Risk of cancer with cyclosporine in psoriasis. Int J Dermatol 1997;36(1 Suppl):15-7.
121. Van de Kerkhof PCM, De Rooij MJM. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol 1997;136:275-8.
122. Vandercam B, Lachapelle JM, Janssens P, et al. Kaposi's sarcoma during immunosuppressive therapy for atopic dermatitis. Dermatology 1997;194:180-4.
123. Oxholm A, Thomsen K, Menné T. Squamous cell carcinomas in relation to cyclosporin therapy of non-malignant skin disorders. Acta Derm Venereol Suppl (Stockh) 1989;69:89-90.
124. Korstanje MJ, van der Staak WJBM. High cumulative dose of ultraviolet radiation is a contraindication for cyclosporin treatment [letter]. Clin Exp Dermatol 1990;15:76.
125. Scaparro E, Borghi S, Rebora A. Kaposi's sarcoma after . immunosuppressive therapy for bullous pemphigoid. Dermatologica 1984;169:156-9.
126. Black HS, deGruijl FR, Forbes PD, et al. Photocarcinogenesis: an overview. J Photochem Photobiol 1997;40:29-47.
127. Bouwes Bavinck JN. Epidemiological aspects of immunosuppression: role of exposure to sunlight and human papillomavirus on the development of skin cancer. Hum Exp Toxicol 1995;14:98.
128. Boyle J, MacKie RM, Briggs JD, et al. Cancer, warts, and sunshine in renal transplant patients. Lancet 1984;1:702-5.
129. Kelley GE, Meikle W, Shell AGR. Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation. Br J Dermatol 1987;117:429-40.
130. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
131. Noonan FP, De Fabo EC. Immunosuppression by ultraviolet B radiation: initiation by urocanic acid. Immunol Today 1992;13:250-4.
132. Cruz PD Jr, Bergstresser PR. Ultraviolet radiation, Langerhans' cells, and skin cancer: conspiracy and failure. Arch Dermatol 1989;125:975-9.
133. Kripke ML. Immunological responsiveness induced by ultraviolet radiation. Immunol Rev 1984;80:87-102.
134. Pamphilon KH, Alnaqdy AA, Wallington TB. Immunomodulation by ultraviolet light: clinical studies and biological effects. Immunol Today 1991;12:119-23.
135. Bouwes Bavinck JN, Claas FH, Hardie DR, et al. Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia. J Invest Dermatol 1997;108:708-11.
136. McGregor JM, Reddi G, MacDonald D, et al. HLA-A11 in renal allograft recipients with skin cancer. J Invest Dermatol 1992;98:261-2.
137. Glover MT, Bodmer J, Bodmer W, et al. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer. Eur J Cancer 1993;29A:520-4.
138. Bouwes Bavinck JN, Kootte AMM, van der Woude FJ, et al. HLA-A11 associated resistance to skin cancer in renal-transplant recipients. N Engl J Med 1990;323:1350.
139. Bouwes Bavinck JN, Robertson I, Wainwright RW, et al. Excessive numbers of skin cancers and pre-malignant skin lesions in an Australian heart transplant recipient. Br Heart J 1995:74:468-70.
140. Czamecki D, Watkins F, Leahy S, et al. Skin cancers and HLA frequencies in renal transplant recipients. Dermatology 1992;185:9-11.
141. Noel JC, Detremmerie O, Peny MO, et al. Transformation of common warts into squamous cell carcinoma on sunexposed areas in an immunosuppressed patient. Dermatology 1994:189:308-11.
142. Euvrard S, Chardonnet Y, Pouteil-Noble CP, et al. Skin malignancies and human papillomaviruses in renal transplant recipients. Transplant Proc 1993;25:1392-3.
143. Höpfl R, Bens G, Wieland U, et al. Human papillomavirus DNA in non-melanoma skin cancers of a renal transplant recipient: detection of a new sequence related to epidermodysplasia vemiciformis associated types. J Invest Dermatol 1997:108:53-6.
144. Stark LA, Arends MJ, McLaren KM, et al. Prevalence of human papillomavirus DNA in cutaneous neoplasms from renal allograft recipients supports a possible viral role in tumor promotion. Br J Cancer 1994:69:222-9.
145. Shamanin V, zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996:88:802-11.
146. Shamanin V, Glover M, Rausch C, et al. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res 1994:54:4610-3.
147. Purdie KJ, Sexton CJ, Proby CM, et al. Malignant transformation of cutaneous lesions in renal allograft patients: a role for human papillomavirus? Cancer Res 1993:53:5328-33.
148. Pierceall WE, Goldberg LH, Anathaswamy HN. Presence of human papilloma virus type 16 DNA sequences in human nonmelanoma skin cancers. J Invest Dermatol 1991;97:880-4.
149. Blessing K, McLaren KM, Benton EC, et al. Histopathology of skin lesions in renal allograft recipients-an assessment of viral features and dysplasia. Histopathology 1989;14:12939.
150. Bouwes Bavinck JN, Gissman L, Claas FHJ, et al. Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients. J Immunol 1993:151:1579-86.
151. Pelisson I, Soler C, Chardonnet Y, et al. A possible role for human papillomaviruses and c-inyc, c-Ha-ras, and p53 gene alterations in malignant cutaneous lesions from renal transplant recipients. Cancer Detect Prev 1996;20:20-30.
152. de Jong-Tieben LM, Berkhout RJM, Smits HL, et al. High frequency of detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol 1995;105:367-71.
153. Tieben LM, Berkhout RJM, Smits HL, et al. Detection of epidermodysplasia verruciformis-like human papillomavirus types in malignant and premalignant skin lesions of renal transplant recipients. Br J Dermatol 1994;131:226-30.
154. Soler C, Chardonnet Y, Euvrard S, et al. Evaluation of human papillomavirus type 5 on frozen sections of multiple lesions from transplant recipients with in situ hybridization and non-isotopic probes. Dermatology 1992;184:248-53.
155. Cathomas G, Tamm M, McGandy CE, et al. Absence of Kaposi's sarcoma-associated human herpes virus 8 in transplantation-related tumors other than Kaposi's sarcoma. Transpant Proc 1997;29:836-7.
156. Rady PL, Yen A, Rollefson JL, et al. Herpesvirus-like DMA sequences in non-Kaposi's sarcoma skin lesions of transplant patients. Lancet 1995;345:1339-40.
157. Hartevelt MM, Bouwes Bavinck JN, Kootte AMM, et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990;49:506-9.
158. Butt A, Roberts DL. Renal transplant recipients and protection from sun: need for education. Lancet 1997;349:179-80.
159. Penn I. Post-transplant malignancies: clinical preventive measures. In: Schmahl D, Penn I, editors. Cancer in organ transplant recipients. New York: Springer-Verlag; 1991. p 157-60.
160. Black HS, Herd A, Goldberg LH, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med 1994:330:1272-5.
161. Blohmé I, Larkö O. Premalignant and malignant skin lesions in renal transplant patients. Transplantation 1984;37:165-7.
162. Leigh IM, Glover MT. Cutaneous warts and tumours in immunosuppressed patients. J R Soc Med 1995;88:61-2.
163. Yuan Z, Davis A, MacDonald K, et al. Use of acitretin for the skin complications in renal transplant recipients. N Z MedJ 1995;108:255-6.
164. Vandeghinste N, De Bersaques J, Geerts ML, et al. Acitretin as cancer chemoprophylaxis in a renal transplant recipient. Dermatology 1992;185:307-8.
165. Bouwes Bavinck JN, Tieben LM, van der woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995;13:1933-8.
166. Shuttleworth D, Marks R, Griffin PJA, et al. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988;68:717-24.
167. McKerrow KJ, Mackie RM, Lesko MJ, et al. The effect of oral retinoid therapy on the normal human immune system. BrJ Dermatol 1988;119:313-20.
168. Kelly JW, Sabto J, Gurr FW, et al. Retinoids to prevent skin cancer in organ transplant recipients. Lancet 1991;338:1407.
169. Rook AH, Javvorsky C, Nguyen T, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995:59:714-9.
170. Bellman B A, Eaglstein WH, Miller J. Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients. Transplantation 1996;61:173.
171. Euvrard S, Verschoore M, Touraine JL, et al. Topical retinoids for warts and kératoses in transplant recipients. Lancet 1992;340:48-9.
172. English DDR, Armstrong BK, Kricker A, et al. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer 1998;76:628-34.
173. Marks R, Rennie G, Selwood T. The relationship of basal cell carcinomas and squamous cell carcinomas to solar kératoses. Arch Dermatol 1988;124:1039-42.
174. Downham TFII. The shadow rule: a simple method for sun protection. South Med J 1998;91:619-23.
175. Shiner DL, McCoy DF, Goldberg DJ, et al. Mohs micrographic surgery. J Am Acad Dermatol 1998;39:79-97.
176. Benton EC. Therapy of cutaneous warts. Clin Dermatol 1997:15:449-55.
177. Lutzner MA, Gerard O, Dutroquay V, Ducasse MF, Kreis H, Crosnier J. Detection of human papilloma virus type 5 DNA in skin cancers of an immunosuppressed renal allograft recipient. Lancet 1983;2:422-4.
178. Bunney MH, Benton C, Cubie HA, eds. Viral warts: biology and treatment. NY: Oxford University Press; 1992; p 108-115.
179. Gonçalves JCA. 5-Fluorouracil in the treatment of common waits of the hands. Br J Dermatol 1975;92:89-91.
180. Hursthouse MW. A controlled trial on the use of topical 5-fluorouracil on viral warts. Br J Dermatol 1975;92:93-6.
181. Sobh MA, Abd El-Razic MM, Rizc RA, Eid MM, Abd ElHamid IA, Ghoneim MA. Intralesional injection of bleomycin sulphate into resistant warts in renal transplant recipients versus non-transplant warty patients. Acta Derm Venereol Suppl (Stockh) 1991;71:63-6.
182. Hayes ME, O'Keefe EJ. Reduced dose of bleomycin in the treatment of recalcitrant warts. J Am Acad Dermatol 1986;15:1002-6.
183. Lim JT, Goh CL. Carbon dioxide laser treatment of periungual and subungual viral warts. Australas J Dermatol 1992;33:87-91.
184. McBumey EI, Rosen DA. Carbon dioxide laser treatment of verrucae vulgaris. J Dermatol Surg Oncol 1984;10:45-8.
185. Hruza GJ. Laser treatment of warts and other epidermal and dermal lesions. Dermatol Clin 1997;15:487-506.
186. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993;12(Suppl):S328-36.
187. Shepherd FA, Mäher E, Cardella C, et al. Treatment of Kaposi's sarcoma after solid organ transplant. J Clin Oncol 1997:15:2371-7.
188. Holecek MJ, Harwood AR. Radiotherapy of Kaposi's sarcoma. Cancer 1978;41:1733-8.
189. Voss N, Kirn-Sing C. Radiotherapy in the treatment of dermatologie malignancies. Dermatol Clin 1998;16:313-20.
190. Besnard V, Euvrard S, Kanitakis J. Kaposi's sarcoma after liver transplantation. Dermatology 1996;193:100-4.
191. Brambilla, Boneschi V, Fossati S, Ferrucci S, Finzi AF. Vinorelbine therapy for Kaposi's sarcoma in a kidney transplant patient. Dermatology 1997;194:281-3.